on July 17, 2026
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by chronic, symmetrical synovitis that leads to progressive destruction of joint structures, deformity, and severe disability. Classified as a chronic degenerative condition, RA can be managed but not completely eradicated by conventional pharmacological therapies. For this reason, the adoption of an integrated approach that includes Complementary and Alternative Medicine (CAM) is now considered essential to optimize patients' quality of life. Data from Anglo-Saxon medical literature indicate that approximately 38% of people with RA regularly use CAM, a percentage that ranges from 60% to 90% when the analysis is extended to patient cohorts affected by different forms of chronic pain (Alternative Medicine Review). Clinical phytotherapy and guided nutritional intervention (Nutritional Bulletin) represent primary tools in a therapeutic pathway conducted "according to science and conscience," aimed at improving symptoms and reducing the dosages and consequent side effects of synthetic drugs (such as NSAIDs and corticosteroids).
The Gut-Joint Axis: The Key Role of the Microbiota
Scientific evidence from recent years has revolutionized the understanding of the etiopathogenesis of RA, locating one of the main drivers of the autoimmune trigger in the gastrointestinal tract. Experimental models in germ-free animals (lacking microbiota) have demonstrated complete protection from the development of induced arthritis, confirming the causal role of commensal bacteria in the progression of the disease.
In humans, sequencing of the intestinal microbiota has revealed a clear taxonomic divergence between healthy individuals and patients with RA. In patients with new-onset rheumatoid arthritis (new-onset RA), there is a marked overrepresentation of the genus Prevotella, particularly the species Prevotella copri, with a concomitant and significant reduction in protective Bacteroidetes. This homeostatic alteration is not limited to the fecal compartment: comparative clinical studies have highlighted a mirror-image dysbiosis in saliva and dental samples, characterized by the depletion of Haemophilus spp. and a massive proliferation of Lactobacillus salivarius, whose abundance directly correlates with the clinical severity of the pathology in all three investigated biological sites.
Probiotic Modulation of Systemic Inflammation
The use of standardized probiotic microorganisms is part of the clinical rationale to restore the balance of the intestinal barrier to attenuate systemic immune hyperactivation. An important randomized, double-blind, placebo-controlled clinical study, conducted by a research team from the Department of Nutrition, Biochemistry and Diet Therapy of the Tabriz University of Medical Sciences, evaluated the impact of probiotic supplementation on 46 patients with RA (Vaghef-Mehrabany et al., 2014).
Participants took one capsule daily for 8 weeks containing a minimum of 10^8 CFU of Lactobacillus casei 01 or a maltodextrin-based placebo. At the end of the intervention, the group treated with the probiotic showed a statistically significant reduction in the score related to disease activity (Disease Activity Score, p < 0.01) compared to the placebo arm. Immunological analysis documented a clear improvement in the circulating cytokine profile: levels of pro-inflammatory cytokines Tumor Necrosis Factor alpha (TNF-alpha, Interleukin-6 (IL-6), and Interleukin-12 (IL-12) decreased significantly (p < 0.05, while there was a targeted increase in the anti-inflammatory cytokine Interleukin-10 (IL-10) (p < 0.05). This study confirms that microbiota modulation through L. casei 01 is able to mitigate the systemic inflammatory state in RA, positioning itself as a valid adjuvant treatment.
Nutritional Approach and Metabolic Support
RA predominantly affects the female sex, with a peak incidence between 40 and 60 years. From a metabolic point of view, chronic pain, chewing difficulties (in cases of temporomandibular involvement), and the prolonged use of anorexic drugs expose the patient to progressive weight loss and neoplastic-inflammatory cachexia, making it necessary to increase the daily energy intake divided into 5 or 6 small meals.
The nutritional gold standard is represented by the Mediterranean Diet, thanks to its optimal macronutrient balance and the supply of antioxidant molecules. Specific dietary guidelines for RA include:
· Optimization of protein turnover: Increase the share of plant proteins (up to reaching about 20% of the daily caloric intake) to counteract sarcopenia and loss of muscle tone induced by the acute phase of the pathology.
· Omega-3 Polyunsaturated Fatty Acid (PUFA) Supplementation: The daily intake of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) – with recommended dosages of 3 g/day of total Omega-3 and 500 mg/day of DHA – modifies the phospholipid composition of cell membranes. EPA and DHA compete with arachidonic acid for the cyclooxygenase and lipoxygenase enzymatic pathways: while arachidonic acid derivatives generate pro-inflammatory eicosanoids (PGE2, LTB4), EPA and DHA promote the synthesis of series 3 prostaglandins (PGE3) and series 5 leukotrienes (LT5) with pronounced anti-inflammatory activity, in addition to giving rise to inflammation resolution mediators such as resolvins and protectins. A review of 23 clinical studies confirmed that such supplementation reduces joint swelling, the duration of morning stiffness, and the use of NSAIDs. It is worth noting that the protective efficacy of PUFAs (tested in multicenter studies with 2,090 g of EPA and 1,165 g of DHA for 4 months) is optimally expressed in patients with a body weight over 55 kg.
· Vitamin D Status: Maintaining optimal serum levels of Vitamin D (target of about 45 ng/ml) is crucial in RA. This vitamin acts as a powerful immunomodulator, influencing the proliferation of T helper lymphocytes and reducing the synthesis of Th1 cytokines; low blood levels are associated with a marked worsening of the clinical and radiological course of the disease.
Clinical Phytocomplexes and Medicinal Mushrooms in Pain and Inflammation Control
Modern phytotherapy offers standardized solutions capable of selectively interfering with the pathways of inflammation and joint tissue damage.
Boswellia sacra and spp.
Boswellia gum contains pentacyclic triterpenic acids, among which acetyl-11-keto-\beta-boswellic acid (AKBA) stands out. AKBA is an allosteric, direct, and non-competitive inhibitor of the 5-lipoxygenase (5-LOX) enzyme, responsible for the production of inflammatory leukotrienes. Boswellic acids also exert a protective action on cartilage, reducing the degradation of glycosaminoglycans and modulating autoimmune mediators. Clinical studies conducted with standardized extracts at 20-30% AKBA (dosages of 100-250 mg/day for 90 days) have demonstrated pain reductions between 32% and 65%, with a significant improvement in joint functionality visible already after the first week of treatment (Sengupta et al., 2008; Sengupta et al., 2010). Clinical literature reviews confirm the efficacy of Boswellia in RA in reducing morning stiffness, swelling, and the consumption of NSAIDs.
Harpagophytum procumbens (Devil's Claw)
Rich in monoterpene iridoids (arpagoside, arpagide) and phenylethanol derivatives, this phytocomplex selectively inhibits cyclooxygenase-2 (COX-2) and the synthesis of PGE2 and TNF-\alpha, without interfering with COX-1 (thus avoiding the gastrointestinal damage typical of traditional NSAIDs). Its efficacy is particularly marked in models of subacute and chronic inflammation. Clinical trials conducted with 2.6 g/day of standardized extract (equal to 60 mg/day of arpagoside) administered for 16 weeks have highlighted a clear reduction in spontaneous pain and a drastic contraction of the use of synthetic analgesics.
Curcuma longa
Turmeric rhizome contains curcuminoids with extremely high antioxidant and anti-inflammatory potential, capable of exerting a dual inhibition on 5-LOX and COX-2. In a comparative clinical study, a specific preparation based on turmeric administered at the dosage of 1000 mg/day demonstrated superior efficacy in reducing RA symptomatology compared to 100 mg/day of diclofenac sodium in 8 weeks of treatment, showing an optimal safety profile.
Salix spp. (Willow Bark)
It contains stable salicylate precursors (salicin, salicortin, tremulacin) associated with flavonoids and tannins. The standardized dry extract (dosed to provide 120-240 mg/day of salicin) acts by modulating the release of prostaglandins induced by COX-2 and interfering with the formation of bradykinin and pro-inflammatory cytokines in the tissues. Since salicin is a prodrug activated at the intestinal level, the extract does not present the gastric gastrolesive effects of acetylsalicylic acid, showing consolidated clinical efficacy in the treatment of fixed pain and chronic low back pain (Cochrane Meta-analysis, 2007).
Zingiber officinale (Ginger)
Characterized by gingerols and shogaols, ginger operates as a dual COX/LOX inhibitor, suppressing the synthesis of PGE2, thromboxane B2 (TXB2), and TNF-\alpha. Clinical studies conducted with 1 g/day of dry extract for 3 months have confirmed a significant reduction in pain and joint inflammation in patients with rheumatic disorders.
Integrated Mycotherapy: Reishi, Agaricus, and Shiitake
The clinical application of medicinal mushrooms (Ganoderma lucidum, Agaricus blandei, Lentinula edodes) exploits the high concentration of beta-glucans of medium and high molecular weight to induce immunomodulation. In autoimmune diseases such as RA, the synergy of these three macrofungi acts by normalizing the unbalanced immune response, reducing pathological immunoglobulins (IgE/IgG) and humoral markers of inflammation in a time frame of 3-4 months, without exhibiting toxicity. The concomitant administration of Vitamin C is indicated to break the bonds of the fungal polymers, increasing their intestinal bioavailability.
Other Phytotherapeutic Aids: Rosehip, Uncaria, and Withania
· Rosehip: Its berries are rich in galactolipids and polyphenols with anti-inflammatory and antinociceptive action, effective in counteracting the structural deterioration of cartilage in exploratory clinical studies.
· Uncaria tomentosa: The bark contains pentacyclic oxindole alkaloids (POA) with pronounced immunomodulating and antioxidant activity. While inhibiting the inflammatory cascade, its use in RA requires close medical supervision due to the potential effect of overall immune stimulation.
· Withania somnifera (Ashwagandha): It plays a dual tonic and adaptogenic/sedative role, reducing somatization anxiety associated with chronic pain and modulating the musculoskeletal inflammatory pathways typical of autoimmune rheumatic conditions.
· Rosmarinus officinalis: Rosemary extract, rich in rosmarinic and carnosic acids, significantly reduces high-sensitivity C-reactive protein (hs-CRP) in RA patients. Rosmarinic acid acts by inhibiting the activation of the complement system (C3b fraction) at very low doses, while also exerting a gastroprotective effect superior to omeprazole by reducing neutrophil infiltration into the gastric mucosa.
Emerging Evidence: Vaccinium macrocarpon (American Cranberry)
A recent prospective clinical study conducted in Brazil on 41 women with rheumatoid arthritis investigated the effect of daily cranberry juice consumption on disease biomarkers (Thimóteo et al., 2019). The experimental group (n = 23) consumed 500 ml/day of low-calorie cranberry juice for 90 days, while the control group (n = 18) maintained their usual diet. At the end of the follow-up, the intervention group showed a statistically significant reduction in the Disease Activity Score 28 (DAS28, p = 0.048) and serum levels of anti-cyclic citrullinated peptide antibodies (anti-CCP, p = 0.034), a highly specific biomarker of severity and progression of damage in RA. The clinical data confirms the efficacy of cranberry in mitigating the clinical progression of the disease.
Bibliographic References
· Vaghef-Mehrabany, E., Alipour B., Homayouni-Rad A., Sharif S. K., Asghari-Jafarabadi M., Zavvari S. (2014). Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition, 30(4), 430-435.
· Sengupta, K., Alluri, K. V., Satish, A. R., Mishra, S., Golakoti, T., Sarma, K. V., ... & Raychaudhuri, S. P. (2008). A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Research & Therapy, 10(4), R85.
· Sengupta, K., Krishnaraju, A. V., Otimenyin, S. O., Mbonu, O. A., Gde, V., Golakoti, T., & Raychaudhuri, S. P. (2010). Comparative efficacy and safety of NEXRUSH and 5-Loxin in a randomized, double-blind, placebo-controlled clinical trial for the treatment of osteoarthritis of the knee. Minerva Medica, 101(6), 387-397.
· Thimóteo, N. S. B., Iryioda, T. M. V., Alfieri, D. F., et al. (2019). Cranberry Juice Decreases Disease Activity in Women With Rheumatoid Arthritis. Nutrition, 60, 112-117.
· Reed, G. W., Leung, K., Rossetti, R. G., Vanbuskirk, S., Sharp, J. T., & Zurier, R. B. (2014). Treatment of rheumatoid arthritis with marine and botanical oils: An 18-month, randomized, and double-blind trial. Evidence-Based Complementary and Alternative Medicine, 2014, Article ID 857456.
· Chrubasik, S., Künzel, O., Model, A., Conradt, C., & Black, A. (2004). Treatment of low back pain with a herbal medicine of Harpagophytum procumbens: a randomised clinically controlled, double-blind comparison with Vioxx. Phytomedicine, 11(7-8), 584-591.
· Gagnier, J. J., Oltean, H., van Tulder, M. W., Berman, B. M., & Chrubasik, S. (2007). Herbal medicine for low back pain. Cochrane Database of Systematic Reviews, (4), CD004521.
